MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education
division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC
Markets: RMTG), today announced ISSCA 129, its return to Dubai, United Arab Emirates, December
4–5 at the Hyatt Regency Dubai Creek Heights, closing ISSCA’s international conference calendar for
the year.
The Dubai conference caps a year that included ISSCA events across more than a dozen countries —
including Paraguay, Pakistan, Portugal, Brazil, the Dominican Republic, Peru, Argentina, Turkey,
Mexico, Bolivia, and Colombia — alongside continued growth of its Online Academy and
certification programs. Final totals for physicians trained and certifications issued across the year will
be confirmed at time of publication.
ISSCA positioned Dubai as a fitting close to the calendar given the UAE’s role as a regional hub
connecting Middle Eastern, South Asian, and African physician communities to ISSCA’s education
network.
“Closing the year in Dubai lets us look back at a genuinely global conference calendar — Latin
America, the Middle East, and everywhere in between,” said David Christensen, Chief Executive
Officer and President of Regenerative Medical Technology Group, Inc. “It’s also where we start
planning next year’s expansion.”
INVESTOR TAKEAWAYS
- Natural anchor for the year’s cumulative, verified operating metrics — the single best release in the
pipeline for a “year in review” investor framing - UAE positioning reinforces Middle East market relevance also referenced in the MUSE cell
release (#2) - Should be scheduled last in the pipeline’s publication order, after all other 2026 events have
actually occurred, so any roll-up figures are real
STRATEGIC / COMMERCIAL SIGNIFICANCE
This is the pipeline’s natural “year in review” release — it should be drafted last, after the other 2026
events have actually happened, so that any cumulative figures cited are real rather than projected.
ABOUT REGENERATIVE MEDICAL TECHNOLOGY GROUP, INC.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative
medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global
Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application
(ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across
more than 30 countries, combining biologics and regenerative-medicine product commercialization,
physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
ABOUT ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global
Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
